Floatz logo

Ompenaclid

Gastrointestinal Neoplasms

Inspirna, Inc.Small moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Gastrointestinal Neoplasms cohort.

Asset / SponsorPhaseRating
Capecitabine
China Medical University, China
Phase 3BB
Sorafenib
Sichuan Cancer Hospital and Research Institute
Phase 3BB
FLUOROURACILUM
Janssen Research & Development, LLC
Phase 3BB
Irinotecan
Pfizer
Phase 3BB
Catequentinib
Zhejiang University
Phase 2B

View all 50 →

Same molecule, other indications

Ompenaclid is also rated in:

metastasis from malignant tumor of colonDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
gastric neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →